(GEVA) (GEVA) Stock Price, News & Analysis

Company Overview

Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GEVA Stock Analysis - Frequently Asked Questions

How were (GEVA)'s earnings last quarter?

(GEVA) (NASDAQ:GEVA) issued its earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.71) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to the consensus estimate of $1.25 million.

What other stocks do shareholders of (GEVA) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (GEVA) investors own include AutoZone (AZO), Intuitive Surgical (ISRG), U-Haul (UHAL), Regeneron Pharmaceuticals (REGN), Netflix (NFLX), AT&T (T) and Novavax (NVAX).

Company Calendar

• Last Earnings: 2/26/2015
• Today: 6/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GEVA
• CIK: 911326
• Web: www.synageva.com
• Phone: +1-781-3579900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A